Compare Tango Therapeutics Inc. (TNGX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Thomson Reuters Corp — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Thomson Reuters Corp trades at $105.4 (market cap $45.37B). The key difference: Thomson Reuters Corp is far larger — about 12.1× Tango Therapeutics Inc.'s market cap, and Thomson Reuters Corp pays a 2.49% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Thomson Reuters Corp for 63 Days on average.
| TNGX | TRI | |
|---|---|---|
Market Cap | $3.75B | $45.37B |
Volume | 9,619,106 | 729,201 |
Sector | Health | Industrials |
52-Week High | $32.90 | $163.45 |
52-Week Low | $7.50 | $76.55 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $2.77B | $47.98B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Thomson Reuters (TRI) trades at $105.40, up 1.1% today, with a bullish technical outlook and strong analyst support. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, while maintaining robust profitability with a 21.22% net income margin. Recent strategic moves include divesting its Global Print business to focus on technology and launching a proprietary AI model, reinforcing its competitive edge in legal and tax solutions.
The stock offers upside to the consensus price target of $128.60, supported by recurring revenue growth and AI expansion, but faces risks from cybersecurity incidents and integration challenges from recent divestitures. Valuation multiples like a P/E of 27.69 suggest premium pricing, requiring sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
